Fore Biotherapeutics is a clinical-stage targeted oncology company developing precision medicines for patients with difficult-to-treat cancers. The company’s lead asset, plixorafenib, is an investigational next-generation BRAF inhibitor designed to address a broad range of BRAF alterations, including both V600 and non-V600 mutations, while overcoming key limitations of earlier-generation BRAF inhibitors. Plixorafenib has demonstrated encouraging clinical activity across multiple BRAF-altered tumor types and is being advanced through a global registrational basket trial. By focusing on genetically defined cancers with significant unmet medical needs, Fore Biotherapeutics aims to expand the reach of targeted therapy to patient populations that have historically had limited treatment options.